Insider Selling: Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells 1,018 Shares of Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 1,018 shares of the firm’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $30.87, for a total transaction of $31,425.66. Following the completion of the sale, the general counsel owned 24,594 shares in the company, valued at $759,216.78. This represents a 3.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Jonathan Allan also recently made the following trade(s):

• On Friday, December 5th, Jonathan Allan sold 8,785 shares of Stoke Therapeutics stock. The shares were sold at an average price of $31.29, for a total transaction of $274,882.65.
• On Wednesday, December 3rd, Jonathan Allan sold 2,292 shares of Stoke Therapeutics stock. The stock was sold at an average price of $30.65, for a total transaction of $70,249.80.
• On Tuesday, December 2nd, Jonathan Allan sold 2,284 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.78, for a total transaction of $68,017.52.
• On Friday, October 3rd, Jonathan Allan sold 10,000 shares of Stoke Therapeutics stock. The shares were sold at an average price of $25.07, for a total transaction of $250,700.00.

Stoke Therapeutics Stock Down 0.6%

Shares of NASDAQ:STOK traded down $0.18 during trading on Friday, reaching $30.87. 602,753 shares of the company traded hands, compared to its average volume of 917,923. The company’s 50 day moving average is $28.90 and its two-hundred day moving average is $19.69. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $38.69. The firm has a market capitalization of $1.76 billion, a PE ratio of 46.07 and a beta of 1.14.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.11). The company had revenue of $10.63 million during the quarter, compared to analyst estimates of $6.06 million. Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%. As a group, research analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of STOK. Generali Investments Management Co LLC purchased a new position in shares of Stoke Therapeutics during the 3rd quarter valued at about $41,000. BNP Paribas Financial Markets grew its position in Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after acquiring an additional 1,668 shares during the last quarter. Tower Research Capital LLC TRC grew its position in Stoke Therapeutics by 461.0% during the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after acquiring an additional 3,591 shares during the last quarter. AlphaQuest LLC purchased a new position in shares of Stoke Therapeutics during the first quarter worth approximately $72,000. Finally, US Bancorp DE lifted its holdings in shares of Stoke Therapeutics by 9,743.9% in the 1st quarter. US Bancorp DE now owns 11,222 shares of the company’s stock worth $75,000 after acquiring an additional 11,108 shares during the last quarter.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Canaccord Genuity Group increased their price target on Stoke Therapeutics from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. BTIG Research reaffirmed a “buy” rating and set a $39.00 target price on shares of Stoke Therapeutics in a report on Wednesday, November 5th. Wedbush raised their price target on shares of Stoke Therapeutics from $22.00 to $32.00 and gave the company an “outperform” rating in a report on Wednesday, November 5th. Weiss Ratings restated a “hold (c)” rating on shares of Stoke Therapeutics in a research report on Monday. Finally, JPMorgan Chase & Co. upped their price target on shares of Stoke Therapeutics from $15.00 to $25.00 and gave the stock a “neutral” rating in a report on Monday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, Stoke Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $31.00.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.